Tag Archives: Ventrus Biosciences

East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More

(Updated, 9:05 am ET) The East Coast got buried in snow this week—again—but biotech activity was raging regardless. More IPOs priced (of course). A new high-profile startup emerged from stealth. A small acquisition wowed Wall Street. Those headlines and more below: —Third Rock Ventures has had success so far with its first gene therapy portfolio […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More

Ventrus Struggles to Reassure Street After Loss of Hemorrhoid Drug

When New York-based Ventrus Biosciences went public in December 2010, the promise that the company might have the first FDA-approved prescription drug to treat hemorrhoids sent the stock from $6 to as high as $21 a share, before it settled into a trading range of $10 to $12. So when Ventrus (NASDAQ: VTUS) announced on […]

Posted in National blog main, New York, New York blog main | Tagged , , , , , , , , , , , | Comments Off on Ventrus Struggles to Reassure Street After Loss of Hemorrhoid Drug

Ventrus Attracts Investors With Hemorrhoid Drug and Two Other Late-Stage Drug Candidates

Ventrus Biosciences CEO Russell Ellison jokes that he doesn’t know how his mother would have reacted if he told her 20 years ago what he’d be doing today. Jokes help when you work at a place like Ventrus (NASDAQ: VTUS), where the lead drug candidate may just become the first ever FDA-approved prescription product to […]

Posted in National blog main, New York, New York blog main | Tagged , , , , , , , , , , | 5 Comments